Promising Alzheimer’s drugs are
ready for late-stage clinical trials

Virtually all adults with Ds develop the neuropathology (amyloid beta plaques and tau tangles) consistent with Alzheimer’s by their 40s. At age 40, 10% already have Alzheimer’s dementia. Without necessary resources, Pharma will not be able to measure how well any therapies work for people with Down syndrome and will delay the initiation of late stage clinical trials in Down syndrome with their promising Alzheimer’s therapies.

LuMind RDS has funded a grant to support the planning effort required to establish a Down Syndrome Clinical Trial Consortium, focused initially on advancing Alzheimer’s therapies for individuals with Down syndrome.

Your Donation Helps

Down syndrome research offers opportunities for people of all ages with Down syndrome. Your support is essential to finding safe, effective drugs and interventions to improve health and independence. Your gift is crucial to furthering these breakthroughs.

We’ve designed a clear path to therapies

Based on recent scientific findings, our CEO, board and world renowned scientific advisors have established four priorities for funding research. We’re focused on exciting research targeting the root cause with the objective of improving health and independence for our loved ones throughout their lifetimes. Our four priorities are: preventing Alzheimer’s onset, improving cognition, developing gene therapies, and advancing understanding.

LuMind RDS News

  McCordsville mom’s cornhole tournament benefits Down syndrome research

   McCordsville mom’s cornhole tournament benefits Down syndrome research INDIANAPOLIS (July 31, 2018) – McCordsville, Indiana mother and Down syndrome advocate, Mari Kennedy, is helping accelerate breakthroughs in Down syndrome and Alzheimer’s disease research for her son, Ryan, with a few bags of corn. “I learned a few years ago that Down syndrome research received …

Read More

What people are saying about us.

“I never thought I would be in a position to say, ‘We are going to take therapies forward to directly treat Down syndrome.’ Now I think that is the case. We really are in the early stages of a revolution in understanding the basis for many of the features that occur in Down syndrome.”

Dr. Roger Reeves, Johns Hopkins